Chronic Obstructive Pulmonary Disease Clinical Trial
Official title:
Technical Validity and Clinical Feasibility of Using a Telerehabilitation System Using Advanced Telehealth Technologies
This prospective study will be held in two steps. The aim of the first step is to assess the technical validity of transmitting data remotely from different devices connected to a telerehabilitation system. These will include real-time oximetry data during exercise on a cycle ergometer (heart rate and transcutaneous oxygen saturation) as well as daily step count from a commercially available physical activity tracker. The aim of the second step of the study is to assess the clinical feasibility of using the telerehabilitation system in real life conditions (in the home environment). Briefly, participants will benefit from a eight weeks pulmonary rehabilitation program performed at home, using the telerehabilitation system. Further details about the content of the program and the outcomes are provided below.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | March 31, 2024 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age superior to eighteen years. - Stable (> four weeks) chronic obstructive pulmonary disease, GOLD stage II to IV - Referred to pulmonary rehabilitation (no contraindication to exercise training on a cycle ergometer). - With or without oxygen during exercise. Specific inclusion criteria for the first step of the study: - Able to perform forty-five minutes of exercise training on a cycle ergometer. Specific inclusion criteria for the second phase of the study: - Person of legal age who may be present during home exercise sessions (relatives). Non-inclusion Criteria: - Pregnancy or likely to be. - Guardianship. - Unable to consent. - Referred to pulmonary rehabilitation before lung cancer surgery. - Referred to pulmonary rehabilitation before lung volume reduction surgery scheduled in the next few months. Exclusion Criteria: - Consent withdrawal |
Country | Name | City | State |
---|---|---|---|
France | ADIR Association | Bois-Guillaume | ADIR Association |
Lead Sponsor | Collaborator |
---|---|
ADIR Association | CogSci, Groupe Havrais d'Aide aux Handicapés Respiratoires, KerNel Biomedical, Union des Kinésithérapeutes Respiratoires |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Technical validity of the data transmitted remotely - pulse oximeter - concordance between datasets. | Comparison of paired datasets between the data recorded locally within the internal memory of the pulse oximeter and those collected from the telerehabilitation system. | Data will be recorded immediately after the intervention. | |
Primary | Technical validity of the data transmitted remotely - physical activity tracker - concordance between datasets. | Comparison of paired dataset between the daily data, either automatically collected from the telerehabilitation system or self-reported by the participant (visually displayed on the physical activity tracker). | Data will be recorded immediately after the intervention. | |
Primary | Technical validity of the data transmitted remotely - pulse oximeter - proportion of sessions transmitted. | The number of exercise sessions retrieved from the telerehabilitation system will be expressed in relation to the number of sessions performed. | Data will be recorded immediately after the intervention. | |
Primary | Technical validity of the data transmitted remotely - physical activity tracker - proportion of sessions transmitted. | The number of days with physical activity data retrieved from the telerehabilitation system will be expressed in relation to the number of days that the tracker has been worn by the participant. | Data will be recorded immediately after the intervention. | |
Primary | Technical validity of the data transmitted remotely - pulse oximeter - proportion of common usable data. | The proportion of data without artefacts will be compared between datasets. Artefacts will be identified for heart rate when values indicate two hundred fifty beats per minute and for transcutaneous oxygen saturation when values indicate hundred percent. | Data will be recorded immediately after the intervention. | |
Primary | Technical validity of the data transmitted remotely - pulse oximeter - number of session required to be autonomous when using the system. | Participants will be taught to use the system and they will be requested to set data collection autonomously during the four next sessions. They will be considered autonomous when they will be able to set data collection autonomously without error. The number of sessions (after the first session) required to reach autonomy will be collected. | Data will be recorded immediately after the intervention. | |
Secondary | Endurance exercise capacity - constant workload exercise testing. | Time to exhaustion (in second) during a constant workload exercise testing on a cycle ergometer at seventy-five percent of the maximal workload achieved during a previously performed incremental cardiopulmonary exercise testing. | Baseline and immediately after the intervention. | |
Secondary | Endurance exercise capacity - six-minute walking test. | Number of meters performed during the six-minutes walking test, performed in a thirty metre long corridor. | Baseline and immediately after the intervention. | |
Secondary | Endurance exercise capacity - six-minute stepper test. | Number of steps performed during the six-minutes stepper test. | Baseline and immediately after the intervention. | |
Secondary | Maximal voluntary isometric quadriceps force. | Data will be recorded using a handheld manometer. | Baseline and immediately after the intervention. | |
Secondary | Self-reported quality of life. | Saint George's Respiratory Questionnaire. | Baseline and immediately after the intervention. | |
Secondary | Functional dyspnea. | Modified Medical Research Council dyspnea scale. | Baseline and immediately after the intervention. | |
Secondary | Health status. | Chronic obstructive pulmonary disease Assessment Test. | Baseline and immediately after the intervention. | |
Secondary | Anxiety. | Hospital And Anxiety questionnaire - anxiety sub scale. | Baseline and immediately after the intervention. | |
Secondary | Depression. | Hospital And Anxiety questionnaire - depression sub scale. | Baseline and immediately after the intervention. | |
Secondary | Cognitive Function. | Montreal Cognitive Assessment test. | Baseline and immediately after the intervention. | |
Secondary | Objective physical activity. | Objective physical activity will be assessed using a physical activity tracker (different from the one used with the telerehabilitation system) and expressed as daily step count over a ten-day period. A given day will be considered as valid if the device is worn at least eight hours and the outcome will be considered as valid for a given participant if the measurement includes at least four valid week days. | Baseline and immediately after the intervention. | |
Secondary | Adherence - exercise training. | Adherence will be assessed as the number of exercise training sessions performed in relation to the number of sessions prescribed. | Data will be collected through study completion, an average of 8 weeks. | |
Secondary | Adherence - self-management education. | Adherence will be assessed as the number of self-management education sessions performed in relation to the number of sessions prescribed. | Data will be collected through study completion, an average of 8 weeks. | |
Secondary | Adherence - symptoms monitoring questionnaires. | Adherence will be assessed as the number of days with fulfilled questionnaires relative to the number of days. | Data will be collected through study completion, an average of 8 weeks. | |
Secondary | Use of the telerehabilitation system. | Logs related to the different components of the programs will be retrieved from the telerehabilitation system (number of click to each component of the eight-week period). | Data will be collected through study completion, an average of 8 weeks. | |
Secondary | Usability of the system. | Usability of the system will be assessed using the System Usability Scale. | Data will be collected immediately after the intervention. | |
Secondary | Satisfaction - standardized questionnaire. | Satisfaction will be assessed using the Client Satisfaction Questionnaire-8. | Data will be collected immediately after the intervention. | |
Secondary | Satisfaction - purpose designed survey. | Satisfaction will be assessed using purpose designed surveys intended for participants, their relatives and healthcare professional in charge of telerehabilitation program (Lickert scale). | Data will be collected immediately after the intervention. | |
Secondary | Emotional perception of the system. | Emotional perception of the system will be assessed using Emocards. | Data will be collected immediately after the intervention. | |
Secondary | Participant's flow. | Participant's flow with the system will be assessed using the FKS scale from Rheinberg et al. (2003). | Data will be collected immediately after the intervention. | |
Secondary | Motivation to participate in the program using the telerehabilitation system. | Motivation will be assessed through a one hour semi-directed interview. | Data will be collected immediately after the intervention. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|